Fresenius expands prefilled syringe portfolio

Fresenius (NYSE:FMS) business group Fresenius Kabi said today that it added its heparin sodium injection to the company’s Simplist prefilled syringe portfolio. The prefilled syringe for subcutaneous and intravenous bolus injections expands Fresenius Kabi’s available Heparin formulations.

The Lake Zurich-Ill. company’s Simplist syringes have a 2-year shelf life and do not require any assembly or point-of care preparation.

“Delivering the right drug at the right dose is always important, particularly with high-alert medications such as heparin,” president & CEO John Ducker said in prepared remarks. “Fresenius Kabi Simplist ready-to-administer prefilled syringes help promote safe practices and can minimize medication errors by reducing drug preparation steps and vial-to-syringe transfers.”

Earlier this week, Fresenius Kabi said it landed a 5-year exclusive distribution deal with Terumo Corp. (TYO:4543) to launch Fresenius’ CATSmart autotransfusion system in the US.

Fresenius said that its CATSmart autotransfusion device, which re-infuses a surgical patient’s own blood, boasts continuous-flow technology, 3 wash programs, an auto-start function and sensors for automatic processing. The companies did not release the terms of the deal, but Terumo Cardiovascular will distribute the devices throughout the U.S.